| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32f57a53515b98afbb284cb39a2f17f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b617873e2c2480df011bed7f827ef5b6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-06 |
| filingDate |
2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9b2db135b6f25aa153f6005d8263576 |
| publicationDate |
2009-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009067225-A2 |
| titleOfInvention |
Boceprevir derivatives for the treatment of hcv infections |
| abstract |
This invention relates to novel compounds that are peptides derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel peptides that are derivatives of boceprevir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an HCV NS3/NS4A protease inhibitor, such as boceprevir. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010138889-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105001302-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013178682-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102712644-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2483273-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011038283-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2483273-A1 |
| priorityDate |
2007-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |